Richard A. Larson to Leukemia, B-Cell
This is a "connection" page, showing publications Richard A. Larson has written about Leukemia, B-Cell.
Connection Strength
0.369
-
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 01; 101(1):6-14.
Score: 0.208
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40.
Score: 0.052
-
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15; 20(10):2441-52.
Score: 0.052
-
Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. Cancer Res. 1994 Sep 15; 54(18):4999-5004.
Score: 0.030
-
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol. 1992 Nov; 10(11):1821.
Score: 0.027